Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00029224
NCT00029224
Completed
Phase 4

A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions

Novartis7 sites in 1 country500 target enrollmentOctober 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast CancerMultiple MyelomaProstate Cancer
Drugszoledronic acid

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Novartis
Enrollment
500
Locations
7
Primary Endpoint
Pain score assessed by change from baseline
Status
Completed
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Registry
clinicaltrials.gov
Start Date
October 2001
End Date
November 2002
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Novartis
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Pain score assessed by change from baseline

Secondary Outcomes

  • Quality of life
  • Time in infusion chair
  • Safety assessed by adverse events (AEs)

Study Sites (7)

Loading locations...

Similar Trials

Unknown
Not Applicable
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)Bone MetastasesNeuroendocrine Neoplasm
NCT04720391European Institute of Oncology500
Recruiting
Not Applicable
Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT CohortBone Metastases
NCT02356497UMC Utrecht2,500
Unknown
Phase 2
Study of Anlotinib in Patients With Primary Malignant Bone TumorsNeoplasm of Bone
NCT03527888Chia Tai Tianqing Pharmaceutical Group Co., Ltd.40
Completed
Phase 3
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast CancerBreast Cancer
NCT00320710Novartis Pharmaceuticals416
Recruiting
Not Applicable
Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone MetastasesBreast Neoplasm FemaleNeoplasm MetastasisSpinal Neoplasms
NCT05244382Universidad de Granada58